MAMahwish Arshad

Mahwish Arshad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahwish Arshad has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Structure-Based Virtual Screening and Computational Evaluation of Putative Mushroom-Associated Natural Compounds as Janus Kinase 1 (JAK1) Inhibitors: An In Silico Study

    by Bushra Shakoor, Ali Irfan, Muhammed Tilahun Muhammed, Huma Hameed, Ayesha Amin, Sadaf Ahmad, Mahwish Arshad, Aisha Sethi, Laila Rubab, Yousef A. Bin Jardan

    Introduction/Objective: Janus kinase 1 (JAK1) is a key controller and regulator of cytokinemediated immune responses and an effective therapeutic target in autoimmune and inflammatory diseases. In the present study, an in silico workflow was implemented to identify secondary metabolites of mushrooms as prospective JAK1-binding compounds. This integrated computational-aided drug discovery (CADD) approach was used to evaluate their binding affinity scores, interactions, pharmacokinetic properties, structural stability, toxicity, and electronic characteristics. Methods: An in-silico workflow was employed by employing molecular docking against two JAK1 crystal structures (PDB IDs: 6DBN and 6N7A) in a focused virtual library, and then pharmacokinetic absorption, distribution, metabolism, and excretion (ADME) prediction, toxicity analysis, molecular dynamics (MD) simulation, MM/PBSA binding free energy estimation, and density functional theory (DFT) analysis were performed. Results: Various compounds, such as Vibralactone Z1, SF2738 B, and Lumichrome, showed rather promising docking scores compared to the reference inhibitor Tofacitinib at the ATP-binding pocket of JAK1. ADME profiling and toxicity modeling predicted acceptable oral drug-like properties and high gastrointestinal absorption for the selected candidates. Although Terreumol A produced the highest docking score against one JAK1 structure, integrated evaluation of docking performance, ADME characteristics, toxicity predictions, and drug-likeness properties identified Vibralactone Z1, Vibrolactone X, SF2738 B, and Lumichrome as the most promising overall lead compounds. Furthermore, MM/PBSA calculations suggested energetically favorable binding, particularly for the 6DBN–SF2738 B complex, while 200-ns molecular dynamics simulations demonstrated moderate structural stability of the selected ligand–protein complexes. DFT analysis showed that Lumichrome and SF2738B had lower HOMO-LUMO energy gaps and good electronic descriptors, indicating increased electronic flexibility in the catalytic pocket. Discussion: The integrated computational findings suggest that selected mushroom-derived metabolites possess favorable binding affinity, pharmacokinetic properties, structural stability, and electronic characteristics that support their potential as JAK1 inhibitor scaffolds. These structurally diverse natural compounds provide valuable starting points for the rational design and optimization of novel JAK1-targeted therapeutics. However, the findings are based entirely on computational predictions and should be interpreted as hypothetical until experimentally validated. Conclusion: This CADD approach identified Vibralactone Z1, SF2738 B, and Lumichrome as the most promising and putative mushroom-derived lead compounds for JAK1 inhibition based on data presented in this study through computational analyses. These results highlight their potential for further drug development: biochemical, cellular, in vitro, and in vivo studies are required to confirm their inhibitory activity, safety, and therapeutic efficacy.

  • Open Access

    Antioxidant and neuromodulatory effect of gallic acid prevents anxiety-like symptoms of omeprazole

    by Noreen Samad, Natasha Manzoor, Shehreen Saleem, Saima Khaliq, Umer Ejaz, Mahwish Arshad, Sadaf Ahmad, Bakar Bin Khatab Abbasi, Ali Irfan, Yousef A. Bin Jardan

    This research focuses on the protective impacts of gallic acid (GAL) on OMP-instigated anxiety.


  • Open Access

    Recent advances in the synthetic transformation of benzimidazole scaffolds as privileged pharmacophores for cancer chemotherapy (2020–present)

    by Ali Irfan, Mahwish Arshad, Sami A. Al-Hussain, Ayesha Amin, Iqra Nasim, Sadaf Ahmad, Bakar Bin Khatab Abbasi, Aamal A. Al-Mutairi, Tahira Khalid, Magdi E. A. Zaki


  • Open Access

    Lincomycin HCl-loaded nanoparticles: development, optimization, and incorporation into a nanogel for wound healing

    by Aisha Sethi, Rabia Zaheer, Shazia Akram Ghumman, Asif Massud, Shazia Noureen, Ali Irfan, Mahwish Arshad, Muhammad Khawar Abbas, Mudassar Mazher, Yousef A. Bin Jardan

    The present study focused on developing and evaluating lincomycin HCl (LCH)-loaded chitosan nanoparticles (CSNPs) incorporated into a nanogel system to improve wound healing. CSNPs were prepared via ionic gelation using sodium tripolyphosphate (STPP) as a cross-linker. The optimized formulation showed a mean particle size of 174.3 nm, a polydispersity index (PDI) of 0.267, a zeta potential of +29.4 mV, and a drug entrapment efficiency of 83.7%. FTIR, DSC, and XRD analyses confirmed successful drug encapsulation and stability with no chemical interactions. The formulation demonstrated sustained release (>75% in 24 hours) following non-Fickian kinetics. Antibacterial testing revealed improved efficacy against Staphylococcus aureus and Escherichia coli with inhibition zones of 45 mm ± 2.76 and 38 mm ± 2.15, respectively. In vivo wound healing studies in rats demonstrated almost complete wound closure within 14 days in the treated group, compared to significantly slower healing in the control group. These results show that the LCH–CSNP nanogel provides controlled drug release, effective antimicrobial action, and accelerated wound healing, highlighting its potential as a topical therapeutic platform.


  • Open Access

    Polymeric β-cyclodextrin/alginate/ Colocasia esculenta mucilage (β-CD/Alg/CEM) nanocomposites for the controlled delivery of 5-fluorouracil

    by Maham Anoosh, Shazia Akram Ghumman, Huma Hameed, Shazia Noureen, Rizwana Kausar, Ali Irfan, Maged Ali A. Alrobesh, Mahwish Arshad, Pervaiz Akhtar Shah, Maria Rana, et al.

    5-Fluorouracil (5-FU) is a widely used cytotoxic chemotherapy drug in cancer management; its effectiveness in therapy is reduced due to a short half-life and toxic effects on healthy cells. This study aimed to overcome these limitations by preparing β-cyclodextrin/alginate/Colocasia esculenta mucilage (β-CD/Alg/CEM) nanocomposites containing 5-FU, designed for controlled release in various pH environments. Stable nanocomposites were successfully synthesized through the ionotropic gelation technique, achieving a drug content of 87.33 ± 1.75%, while the %age yield was found to be 79.06 ± 0.53%. Particle size analysis revealed a range of 80–100 nm with a polydispersity index (PDI) of 0.611. The zeta potential analysis showed that the nanocomposites possessed a surface charge of −27.1 mV. The nanocomposites displayed a porous and irregular morphology with a notably rough surface. In the acidic conditions of simulated gastric fluid (pH 1.2), the 5-FU release was markedly less than in the neutral conditions of simulated colorectal fluid (pH 7.4), indicating effective pH-sensitive release properties. The cytotoxic assay confirmed significant tumor–suppressive activity against MCF-7 and minimal effect on normal cells.